Logo

Sutro Signs an Option Agreement with BioNova to Develop and Commercialize STRO-001 for Hematologic Cancers in Greater China

Share this
Sutro Signs an Option Agreement with BioNova to Develop and Commercialize STRO-001 for Hematologic Cancers in Greater China

Sutro Signs an Option Agreement with BioNova to Develop and Commercialize STRO-001 for Hematologic Cancers in Greater China

Shots:

  • Sutro to receive $4M as licensing option fee- ~$200M as an option exercise fee- development- regulatory & commercial milestones along with royalties based on sales of STRO-001 in Greater China. BioNova to get STRO-001 from Sutro under clinical & commercial supply agreements
  • BioNova gets the option to acquire exclusive rights for the development & commercialization of STRO-001 in Greater China & will lead clinical development- regulatory approval & commercialization of STRO-001 in multiple indications- including NHL- MM & leukemia in the licensed countries
  • Sutro will hold development & commercial rights of STRO-001 globally outside of Greater China- including the US

  | Ref: PR Newswire | Image: Linkedin

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions